S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

$16.27
-0.39 (-2.34 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.07
Now: $16.27
$16.97
50-Day Range
$8.25
MA: $11.97
$17.42
52-Week Range
$4.53
Now: $16.27
$22.13
Volume313,600 shs
Average Volume429,892 shs
Market Capitalization$899.26 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More
Accelerate Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.90 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.30 million
Book Value($0.14) per share

Profitability

Net Income$-84,310,000.00
Net Margins-845.43%

Miscellaneous

Employees287
Market Cap$899.26 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXDX shares have increased by 53.3% and is now trading at $16.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Accelerate Diagnostics.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to analyst estimates of $2.40 million. Accelerate Diagnostics had a negative return on equity of 5,681.44% and a negative net margin of 845.43%. View Accelerate Diagnostics' earnings history.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.32 million.

What price target have analysts set for AXDX?

3 Wall Street analysts have issued twelve-month price targets for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $19.00. On average, they expect Accelerate Diagnostics' share price to reach $16.33 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price. View analysts' price targets for Accelerate Diagnostics.

Has Accelerate Diagnostics been receiving favorable news coverage?

Media stories about AXDX stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accelerate Diagnostics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Accelerate Diagnostics.

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $16.27.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $899.26 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.